SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis
Open Access
- 8 July 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7568
Abstract
Bulky tumors remain challenging to treat, and immune checkpoint inhibitors (ICIs), alone or combined with conventional radiotherapy (RT), yield limited efficacy. We present EclipseRT (ERT), an RT technique that delivers low-dose RT (LDRT) to the gross tumor volume (GTV) and stereotactic body RT (SBRT) to selected subvolume(s) within the GTV. Combined with ICIs (iERT), this approach achieves marked control of bulky tumors through the coordinated activity of NK and CD8⁺ T cells. Single-cell RNA sequencing and validation experiments show that the SBRT component robustly induces type I interferon (IFN-I), which activates NK cells to secrete XCL1, thereby recruiting cross-presenting XCR1⁺ dendritic cells (DCs). SBRT also promotes the release of extracellular vesicles carrying neoantigens, enhancing DC cross-presentation and CD8⁺ T-cell responses. The LDRT component further promotes NK and CD8⁺ T-cell recruitment. iERT also induces precursor exhausted CD8⁺ T cells in tumors and tumor-draining lymph nodes. Collectively, iERT activates the IFN-I/NK/DC/CD8⁺ T-cell axis, driving potent antitumor immunity against bulky tumors.Keywords
Funding Information
- National Natural Science Foundation of China (82350128)
This publication has 72 references indexed in Scilit:
- LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2ESMO Open, 2024
- Neutrophil profiling illuminates anti-tumor antigen-presenting potencyCell, 2024
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung CancerJAMA Oncology, 2023
- Progressive immune dysfunction with advancing disease stage in renal cell carcinomaCancer Cell, 2021
- Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell DeathInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune ControlCell, 2018
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint BlockadeCell Reports, 2017
- Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 StudiesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell ImmunotherapyCancer Cell, 2013